Lipocine Inc.

NasdaqCM:LPCN Stock Report

Market Cap: US$19.9m

Lipocine Future Growth

Future criteria checks 2/6

Lipocine is forecast to grow earnings and revenue by 7.9% and 45.5% per annum respectively while EPS is expected to grow by 28.9% per annum.

Key information

7.9%

Earnings growth rate

28.89%

EPS growth rate

Pharmaceuticals earnings growth14.6%
Revenue growth rate45.5%
Future return on equityn/a
Analyst coverage

Low

Last updated23 Jun 2026

Recent future growth updates

Recent updates

Seeking Alpha • Sep 26

Lipocine announces plans to focus on treating CNS disorders, shares rise ~5%

Lipocine (NASDAQ:LPCN) on Monday said the company would now focus on applying its drug delivery technology to develop treatments for central nervous system (CNS) disorders. LPCN stock +4.7% to $0.52 in premarket trading. The company will use its proprietary Lip'ral oral drug delivery technology to advance a pipeline of differentiated products, LPCN said in a statement. The initial focus for the company will be on the delivery of neuroactive steroids, which have been shown to impact CNS function. The company's CNS development portfolio includes LPCN 1154 for the treatment of postpartum depressoin, LPCN 2101 for women with epilepsy and some undisclosed candidates. LPCN said it would stop further investments in its programs for liver diseases and other disorders, and will advance them instead through partnerships. The company believes that its cash securities of $37.4M would be sufficient to support operations and capital expenditure until at least Sept. 30, 2023.
Analysis Article • Feb 22

Does Lipocine (NASDAQ:LPCN) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Sep 14

Is Lipocine (NASDAQ:LPCN) Using Debt Sensibly?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • May 11

When Will Lipocine Inc. (NASDAQ:LPCN) Turn A Profit?

We feel now is a pretty good time to analyse Lipocine Inc.'s ( NASDAQ:LPCN ) business as it appears the company may be...
Analysis Article • Jan 26

Lipocine Inc. (NASDAQ:LPCN): Are Analysts Optimistic?

Lipocine Inc. ( NASDAQ:LPCN ) is possibly approaching a major achievement in its business, so we would like to shine...
Analysis Article • Dec 04

Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

Earnings and Revenue Growth Forecasts

NasdaqCM:LPCN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20281-14N/AN/A1
12/31/20271-19N/AN/A1
12/31/20261-15N/AN/A1
3/31/20262-11-10-10N/A
12/31/20252-10-10-10N/A
9/30/20254-5-5-5N/A
6/30/20254-5-5-5N/A
3/31/20254-5-6-6N/A
12/31/2024110-1-1N/A
9/30/20248-4-5-5N/A
6/30/20245-8-5-5N/A
3/31/20245-9-6-6N/A
12/31/2023-3-16-12-12N/A
9/30/2023-3-16-12-12N/A
6/30/20230-12-12-12N/A
3/31/20231-11-12-12N/A
12/31/20221-11-12-12N/A
9/30/2022174-1-1N/A
6/30/2022173-5-5N/A
3/31/202216-1-4-4N/A
12/31/202116-1-4-4N/A
9/30/20210-18-17-17N/A
6/30/2021N/A-19-14-14N/A
3/31/2021N/A-19-16-16N/A
12/31/2020N/A-21-15-15N/A
9/30/2020N/A-20-15-15N/A
6/30/20200-18-14-14N/A
3/31/20200-16-12-12N/A
12/31/20190-13N/A-12N/A
9/30/20190-13N/A-11N/A
6/30/2019N/A-12N/A-11N/A
3/31/2019N/A-12N/A-11N/A
12/31/20180-12N/A-12N/A
9/30/20180-14N/A-14N/A
6/30/20180-16N/A-15N/A
3/31/20180-19N/A-17N/A
12/31/2017N/A-21N/A-17N/A
9/30/2017N/A-19N/A-15N/A
6/30/2017N/A-17N/A-14N/A
3/31/2017N/A-17N/A-15N/A
12/31/2016N/A-19N/A-18N/A
9/30/2016N/A-21N/A-19N/A
6/30/2016N/A-24N/A-20N/A
3/31/2016N/A-22N/A-19N/A
12/31/2015N/A-18N/A-15N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LPCN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LPCN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LPCN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LPCN's revenue (45.5% per year) is forecast to grow faster than the US market (13% per year).

High Growth Revenue: LPCN's revenue (45.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LPCN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/12 01:30
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lipocine Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Scott HenryAlliance Global Partners
John NewmanCanaccord Genuity
Corey DavisCanaccord Genuity